Intermittent Recurrent Renal Failure: Diagnosing Atypical Hemolytic Uremic Syndrome

Shannon Davis DO
Lehigh Valley Health Network, Shannon.Davis@lvhn.org

Philip Dunn DO
Lehigh Valley Health Network, Philip.Dunn@lvhn.org

Robert Schreiner DO
Lehigh Valley Health Network, robert.schreiner@lvhn.org

Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine
Part of the Medical Sciences Commons

Published In/Presented At

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Hemolytic uremic syndrome (HUS) is characterized by the clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Atypical Hemolytic Uremic Syndrome (aHUS) refers to non-Shiga-toxin HUS and is a primary thrombotic microangiopathic disease due to chronic, uncontrolled activation of the complement system. Complement-mediated HUS is a relatively rare, life-threatening disorder caused by mutations in the genes that encode complement proteins.

Introduction

A 68-year-old male with a past medical history of three previous hospitalizations for unexplained acute renal failure presented with fever, chills, and a transient rash on his forearms. On admission, his serum creatinine was 0.95 mg/dl. He quickly developed anuric renal failure with a rapidly rising creatinine requiring initiation of hemodialysis. Peripheral smear demonstrated schistocytes. Labs revealed thrombocytopenia, anemia, and hypocomplementemia. A renal biopsy was performed which demonstrated features of membranoproliferative glomerulonephritis and thrombotic microangiopathy. Initial therapy included high dose steroids and the initiation of plasmapheresis, however he has since been started on Eclizumab.

Discussion

The diagnosis of complement-mediated HUS remains challenging and is based on the clinical presentation of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, not meeting criteria for typical HUS and TTP.1 Mutations in proteins that regulate the alternative complement pathway such as Factor H (CFH), membrane cofactor protein (MCP or CD46), and Factor I (IF) have been implicated in causing aHUS.2 In the past, plasma exchange was first line treatment however Eculizumab, a humanized monoclonal antibody to C5, has now been shown to more effective resulting in decreased morbidity.3

References: